SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (12327)11/24/1999 7:43:00 AM
From: Robert K.  Read Replies (1) | Respond to of 17367
 
FYI rbpi21>binds neutralizes,kills(bacteria,endotoxin)
rlbp25>eliminates endotoxin without cd14kick and seems
to potential bpi killing.(think about itsome)

I will call it a one,two punch.
the puzzle is being solved
xoma will own most all of the switches.
note the sequence homology.
in my humble opinion. awesome.
now if we can just get these suckers to market.StandardKs



To: aknahow who wrote (12327)11/24/1999 8:52:00 AM
From: Robert K.  Respond to of 17367
 
I think you missed this one george. Bioptern, a new one one me. I have syspected NO though for a while. And btw, (NO) affects that other organ you got too. Perhaps if things dont work out in trauma,sepsis etc, xoma can get to PFE data on bpi actions in "that"organ functioning. In fact we can put you in charge of doing "visual observations" for them. Standardks
>http://www.shocksocieties.org/meetings/7th_vienna_shockforum/abstracts/Yao.html


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News